iRhythm Technologies Announces Results of GUARD-AF Trial - GlobeNewswire
GUARD-AF trial, using iRhythm's Zio® XT patch for AF screening, showed a 5.0% new AF diagnosis rate vs 3.3% in usual care, with no significant difference in stroke hospitalization due to low event rates and early trial stoppage.
Highlighted Terms
Scripps ResearchDuke Clinical Research InstituteZio ® XT 1oral anticoagulationatrial fibrillation (AF)JACC: Clinical ElectrophysiologyJACC: Clinical ElectrophysiologyEuropean Society of Cardiology (ESC)Bristol-Myers Squibb-Pfizer AllianceJournal of the America College of Cardiology (JACC)Duke Clinical Research InstituteJournal of the America College of Cardiology (JACC)Bristol-Myers Squibb-Pfizer AllianceDuke Universityatrial fibrillation (AF)oral anticoagulationZio XT LTCMDuke UniversityiRhythm TechnologiesZio ® patchEuropean Society of Cardiology (ESC)Scripps ResearchiRhythm Technologies
Related News
iRhythm Technologies Announces Results of GUARD-AF Trial | Morningstar
GUARD-AF trial at ESC Congress 2024 showed Zio XT patch-based LTCM increased AF diagnosis (5.0% vs 3.3%) but no stroke reduction due to low event rates and truncated enrollment.
iRhythm Technologies Announces Results of GUARD-AF Trial - GlobeNewswire
GUARD-AF trial, using iRhythm's Zio® XT patch for AF screening, showed a 5.0% new AF diagnosis rate vs 3.3% in usual care, with no significant difference in stroke hospitalization due to low event rates and early trial stoppage.